Literature DB >> 18006805

Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus.

Lalita Wadhwa1, Mary Y Hurwitz, Patricia Chévez-Barrios, Richard L Hurwitz.   

Abstract

Retinoblastoma, the most common intraocular malignancy of childhood, metastasizes by initial invasion of the choroid and the optic nerve. There is no effective treatment for metastatic retinoblastoma, especially when the central nervous system (CNS) is involved, and prevention of this complication is a treatment priority. Seneca Valley Virus (SVV-001) is a conditionally replication-competent picornavirus that is not pathogenic to normal human cells but can kill human retinoblastoma cells in vitro with an IC(50) of <1 viral particle (vp) per cell. A xenograft murine model of metastatic retinoblastoma was used to examine the therapeutic potential of SVV-001. Histopathologic analysis of ocular and brain tissues after a single tail vein injection of SVV-001 (1 x 10(13) vp/kg) showed effective treatment of choroid and ocular nerve tumor invasion (1 of 20 animals with invasive disease in the treated group versus 7 of 20 animals with invasive disease in the control group; P = 0.017) and prevention of CNS metastasis (0 of 20 animals with CNS metastatic disease in the treated group versus 4 of 20 animals with CNS disease in the control group; P = 0.036). There were no observed adverse events due to the virus in any of the treated animals. SVV-001 may be effective as a treatment of locally invasive and metastatic retinoblastoma.

Entities:  

Mesh:

Year:  2007        PMID: 18006805     DOI: 10.1158/0008-5472.CAN-07-2352

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.

Authors:  Linde A Miles; Laura N Burga; Eric E Gardner; Mihnea Bostina; John T Poirier; Charles M Rudin
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

2.  Structural features of the Seneca Valley virus internal ribosome entry site (IRES) element: a picornavirus with a pestivirus-like IRES.

Authors:  Margaret M Willcocks; Nicolas Locker; Zarmwa Gomwalk; Elizabeth Royall; Mehran Bakhshesh; Graham J Belsham; Neeraja Idamakanti; Kevin D Burroughs; P Seshidhar Reddy; Paul L Hallenbeck; Lisa O Roberts
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

3.  Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Authors:  Charles M Rudin; John T Poirier; Neil N Senzer; Joseph Stephenson; David Loesch; Kevin D Burroughs; P Seshidhar Reddy; Christine L Hann; Paul L Hallenbeck
Journal:  Clin Cancer Res       Date:  2011-02-08       Impact factor: 12.531

4.  Cytolytic replication of echoviruses in colon cancer cell lines.

Authors:  Stina Israelsson; Nina Jonsson; Maria Gullberg; A Michael Lindberg
Journal:  Virol J       Date:  2011-10-14       Impact factor: 4.099

5.  Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.

Authors:  Sangita Venkataraman; Seshidhar P Reddy; Jackie Loo; Neeraja Idamakanti; Paul L Hallenbeck; Vijay S Reddy
Journal:  Structure       Date:  2008-10-08       Impact factor: 5.006

6.  Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

Authors:  J T Poirier; Irina Dobromilskaya; Whei F Moriarty; Craig D Peacock; Christine L Hann; Charles M Rudin
Journal:  J Natl Cancer Inst       Date:  2013-06-05       Impact factor: 13.506

7.  The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.

Authors:  Kevin D Pavelko; Michael P Bell; Lavakumar Karyampudi; Michael J Hansen; Kathleen S Allen; Keith L Knutson; Larry R Pease
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

8.  A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

Authors:  Litian Yu; Patricia A Baxter; Xiumei Zhao; Zhigang Liu; Lalita Wadhwa; Yujing Zhang; Jack M F Su; Xiaojie Tan; Jianhua Yang; Adekunle Adesina; Lazlo Perlaky; Mary Hurwitz; Neeraja Idamakanti; Seshidhar Reddy Police; Paul L Hallenbeck; Susan M Blaney; Murali Chintagumpala; Richard L Hurwitz; Xiao-Nan Li
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

9.  Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.

Authors:  Zhigang Liu; Xiumei Zhao; Hua Mao; Patricia A Baxter; Yulun Huang; Litian Yu; Lalita Wadhwa; Jack M Su; Adekunle Adesina; Lazlo Perlaky; Mary Hurwitz; Neeraja Idamakanti; Seshidhar Reddy Police; Paul L Hallenbeck; Richard L Hurwitz; Ching C Lau; Murali Chintagumpala; Susan M Blaney; Xiao-Nan Li
Journal:  Neuro Oncol       Date:  2013-05-07       Impact factor: 12.300

Review 10.  Targeting pediatric cancer stem cells with oncolytic virotherapy.

Authors:  Gregory K Friedman; Kevin A Cassady; Elizabeth A Beierle; James M Markert; G Yancey Gillespie
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.